179 related articles for article (PubMed ID: 36655118)
21. Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study.
Iinuma K; Kameyama K; Kawada K; Fujimoto S; Takagi K; Nagai S; Ito H; Ishida T; Kawase M; Kawase K; Nakai C; Kato D; Takai M; Nakane K; Koie T
Curr Oncol; 2021 Apr; 28(2):1402-1411. PubMed ID: 33916792
[TBL] [Abstract][Full Text] [Related]
22. Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy.
Burke AM; Carrasquilla M; Jean WC; Collins BT; Anaizi AN; Atkins MB; Gibney GT; Collins SP
Front Oncol; 2021; 11():794615. PubMed ID: 35096594
[TBL] [Abstract][Full Text] [Related]
23. Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma.
Potluri R; Ranjan S; Bhandari H; Johnson H; Moshyk A; Kotapati S
Exp Hematol Oncol; 2019; 8():14. PubMed ID: 31312536
[TBL] [Abstract][Full Text] [Related]
24. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
Motzer RJ; McDermott DF; Escudier B; Burotto M; Choueiri TK; Hammers HJ; Barthélémy P; Plimack ER; Porta C; George S; Powles T; Donskov F; Gurney H; Kollmannsberger CK; Grimm MO; Barrios C; Tomita Y; Castellano D; Grünwald V; Rini BI; McHenry MB; Lee CW; McCarthy J; Ejzykowicz F; Tannir NM
Cancer; 2022 Jun; 128(11):2085-2097. PubMed ID: 35383908
[TBL] [Abstract][Full Text] [Related]
25. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab.
Cohen-Inbar O; Shih HH; Xu Z; Schlesinger D; Sheehan JP
J Neurosurg; 2017 Nov; 127(5):1007-1014. PubMed ID: 28059663
[TBL] [Abstract][Full Text] [Related]
26. Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG.
Glutsch V; Schummer P; Kneitz H; Gesierich A; Goebeler M; Klein D; Posch C; Gebhardt C; Haferkamp S; Zimmer L; Becker JC; Leiter U; Weichenthal M; Schadendorf D; Ugurel S; Schilling B
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450381
[TBL] [Abstract][Full Text] [Related]
27. Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer.
Perez BA; Kim S; Wang M; Karimi AM; Powell C; Li J; Dilling TJ; Chiappori A; Latifi K; Rose T; Lannon A; MacMillan G; Saller J; Grass GD; Rosenberg S; Gray J; Haura E; Creelan B; Tanvetyanon T; Saltos A; Shafique M; Boyle TA; Schell MJ; Conejo-Garcia JR; Antonia SJ
Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):425-435. PubMed ID: 33002543
[TBL] [Abstract][Full Text] [Related]
28. Stereotactic Radiosurgery With Concurrent Immunotherapy in Melanoma Brain Metastases Is Feasible and Effective.
Liermann J; Winkler JK; Syed M; Neuberger U; Reuss D; Harrabi S; Naumann P; Ristau J; Weykamp F; El Shafie RA; König L; Debus J; Hassel J; Rieken S
Front Oncol; 2020; 10():592796. PubMed ID: 33178618
[No Abstract] [Full Text] [Related]
29. Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan.
Paly VF; Hikichi Y; Baker T; Itakura E; Chandran N; Harrison J
J Med Econ; 2020 Dec; 23(12):1542-1552. PubMed ID: 33000994
[TBL] [Abstract][Full Text] [Related]
30. Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma.
Numakura K; Sekine Y; Hatakeyama S; Muto Y; Sobu R; Kobayashi M; Sasagawa H; Kashima S; Yamamto R; Nara T; Akashi H; Tabata R; Sato S; Saito M; Narita S; Ohyama C; Habuchi T
Cancer Med; 2023 Aug; 12(16):16837-16845. PubMed ID: 37403728
[TBL] [Abstract][Full Text] [Related]
31. Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients.
Reichert C; Baldini C; Mezghani S; Maubec E; Longvert C; Mortier L; Quereux G; Jannic A; Machet L; de Quatrebarbes J; Nardin C; Beneton N; Amini Adle M; Funck-Brentano E; Descamps V; Hachon L; Malissen N; Baroudjian B; Brunet-Possenti F;
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686606
[TBL] [Abstract][Full Text] [Related]
32. Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial.
Altan M; Wang Y; Song J; Welsh J; Tang C; Guha-Thakurta N; Blumenschein GR; Carter BW; Wefel JS; Ghia AJ; Yeboa DN; McAleer MF; Chung C; Woodhouse KD; McGovern SL; Wang C; Kim BYS; Weinberg JS; Briere TM; Elamin YY; Le X; Cascone T; Negrao MV; Skoulidis F; Ferrarotto R; Heymach JV; Li J
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37402581
[TBL] [Abstract][Full Text] [Related]
33. Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers.
Joseph RW; Shillington AC; Lee TA; Macahilig CP; Diede SJ; Dave V; Harshaw Q; Scherrer E; Liu FX
J Med Econ; 2020 Feb; 23(2):132-138. PubMed ID: 31750751
[No Abstract] [Full Text] [Related]
34. Adverse Events of Cabozantinib Plus Nivolumab Versus Ipilimumab Plus Nivolumab.
Blas L; Shiota M; Tsukahara S; Nagakawa S; Matsumoto T; Eto M
Clin Genitourin Cancer; 2024 Feb; 22(1):e122-e127.e1. PubMed ID: 37813699
[TBL] [Abstract][Full Text] [Related]
35. Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908.
Dunkel IJ; Doz F; Foreman NK; Hargrave D; Lassaletta A; André N; Hansford JR; Hassall T; Eyrich M; Gururangan S; Bartels U; Gajjar A; Howell L; Warad D; Pacius M; Tam R; Wang Y; Zhu L; Cohen K
Neuro Oncol; 2023 Aug; 25(8):1530-1545. PubMed ID: 36808285
[TBL] [Abstract][Full Text] [Related]
36. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
Piulats JM; Espinosa E; de la Cruz Merino L; Varela M; Alonso Carrión L; Martín-Algarra S; López Castro R; Curiel T; Rodríguez-Abreu D; Redrado M; Gomà M; Rullán AJ; Calvo González A; Berrocal-Jaime A
J Clin Oncol; 2021 Feb; 39(6):586-598. PubMed ID: 33417511
[TBL] [Abstract][Full Text] [Related]
37. Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors.
Winter J; Lenders MM; Gassenmaier M; Forschner A; Leiter U; Weide B; Purde MT; Flatz L; Cozzio A; Röcken M; Garbe C; Eigentler TK; Wagner NB
Cancer Immunol Immunother; 2021 Apr; 70(4):1089-1099. PubMed ID: 33113003
[TBL] [Abstract][Full Text] [Related]
38. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
[TBL] [Abstract][Full Text] [Related]
39. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.
Amaral T; Kiecker F; Schaefer S; Stege H; Kaehler K; Terheyden P; Gesierich A; Gutzmer R; Haferkamp S; Uttikal J; Berking C; Rafei-Shamsabadi D; Reinhardt L; Meier F; Karoglan A; Posch C; Gambichler T; Pfoehler C; Thoms K; Tietze J; Debus D; Herbst R; Emmert S; Loquai C; Hassel JC; Meiss F; Tueting T; Heinrich V; Eigentler T; Garbe C; Zimmer L;
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221017
[TBL] [Abstract][Full Text] [Related]
40. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis.
Xing P; Zhang F; Wang G; Xu Y; Li C; Wang S; Guo Y; Cai S; Wang Y; Li J
J Immunother Cancer; 2019 Dec; 7(1):341. PubMed ID: 31801636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
